[{"polarity": 0, "orig_sen": "METHODS: Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m\u00b2 i.v. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CONCLUSION: FOLFIRI plus bevacizumab combination treatment showed promising efficacy and safety as second-line treatment for metastatic intrahepatic cholangiocarcinoma after failure of the first-line treatment of gemcitabine plus oxaliplatin chemotherapy. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of hepatic arterial infusion (HAI) of gemcitabine plus oxaliplatin as second-line treatment for unresectable locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: We retrospectively analyzed the outcome of 12 consecutive patients with unresectable locally advanced intrahepatic cholangiocarcinoma treated with HAI of gemcitabine (1,000 mg/m(2) over 30 min) followed by oxaliplatin (100 mg/m(2) over 2 h), which was repeated every 2 weeks. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: HAI combining gemcitabine and oxaliplatin showed promising efficacy and safety as second-line treatment for locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Oxaliplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " An 82-year-old man with upper abdominal pain was referred to our hospital because of an elevated serum CEA level and dilatation of the intrahepatic bile ducts on ultrasonography.Computed tomography revealed a hypovascular mass measuring 5.0 cm in size in the lateral section, dilatation of the peripheral intrahepatic bile ducts, and swollen lymph nodes around the lesser curvature of the stomach, the common hepatic artery, and the paraaorta.He was diagnosed with unresectable intrahepatic cholangiocarcinoma, and he received chemotherapy with biweekly gemcitabine plus cisplatin.After 33 courses of the chemotherapy, computed tomography revealed that the tumor size decreased over 63%, and all swollen lymph nodes had almost resolved.He underwent a left hemihepatectomy 1 year 6 months after the start of the chemotherapy.He remains alive and well with no evidence of recurrence, 11 months after resection. ", "drug": "cisplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the value of resin-based yttrium-90 ((90)Y) radioembolization for unresectable and failed first-line chemotherapy (cisplatin plus gemcitabine) intrahepatic cholangiocarcinoma (ICC). ", "drug": "cisplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "We encountered a case of resected gastric cancer, which occurred concomitantly with intrahepatic cholangiocarcinoma after S-1 plus cisplatin chemotherapy, in a patient who was previously diagnosed with metastatic liver tumor before treatment. ", "drug": "cisplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "Gemcitabine plus cisplatin has been the standard chemotherapy for advanced biliary tract cancer, but there is lack of evidence on treatment in patients with intrahepatic cholangiocarcinoma (IHC). ", "drug": "cisplatin", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "Here we report three cases of patients with advanced intrahepatic cholangiocarcinoma progressive after standard chemotherapy and treated with sunitinib 50 mg/d in 6-wk cycles of 4 wk on treatment followed by 2 wk off treatment (Schedule 4/2). ", "drug": "sunitinib", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "Those observations contributed to launch a prospective phase II multicenter trial investigating sunitinib in advanced intrahepatic cholangiocarcinoma (SUN-CK study; NCT01718327). ", "drug": "sunitinib", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": " AIM: To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic cholangiocarcinoma. ", "drug": "Bevacizumab", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 0, "orig_sen": "CONCLUSION: FOLFIRI plus bevacizumab combination treatment showed promising efficacy and safety as second-line treatment for metastatic intrahepatic cholangiocarcinoma after failure of the first-line treatment of gemcitabine plus oxaliplatin chemotherapy. ", "drug": "Bevacizumab", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " An 82-year-old man with upper abdominal pain was referred to our hospital because of an elevated serum CEA level and dilatation of the intrahepatic bile ducts on ultrasonography.Computed tomography revealed a hypovascular mass measuring 5.0 cm in size in the lateral section, dilatation of the peripheral intrahepatic bile ducts, and swollen lymph nodes around the lesser curvature of the stomach, the common hepatic artery, and the paraaorta.He was diagnosed with unresectable intrahepatic cholangiocarcinoma, and he received chemotherapy with biweekly gemcitabine plus cisplatin.After 33 courses of the chemotherapy, computed tomography revealed that the tumor size decreased over 63%, and all swollen lymph nodes had almost resolved.He underwent a left hemihepatectomy 1 year 6 months after the start of the chemotherapy.He remains alive and well with no evidence of recurrence, 11 months after resection. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the value of resin-based yttrium-90 ((90)Y) radioembolization for unresectable and failed first-line chemotherapy (cisplatin plus gemcitabine) intrahepatic cholangiocarcinoma (ICC). ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " We report curative resection of an advanced intrahepatic cholangiocarcinoma that responded well to combined S-1 and gemcitabine chemotherapy(GS therapy). ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "Most importantly, this enzyme was also identified as an independent poor prognostic factor for patients with intrahepatic cholangiocarcinoma, as well as a prognostic biomarker of gemcitabine-treated patients. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "METHODS: Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m\u00b2 i.v. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "CONCLUSION: FOLFIRI plus bevacizumab combination treatment showed promising efficacy and safety as second-line treatment for metastatic intrahepatic cholangiocarcinoma after failure of the first-line treatment of gemcitabine plus oxaliplatin chemotherapy. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "Gemcitabine plus cisplatin has been the standard chemotherapy for advanced biliary tract cancer, but there is lack of evidence on treatment in patients with intrahepatic cholangiocarcinoma (IHC). ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of hepatic arterial infusion (HAI) of gemcitabine plus oxaliplatin as second-line treatment for unresectable locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We retrospectively analyzed the outcome of 12 consecutive patients with unresectable locally advanced intrahepatic cholangiocarcinoma treated with HAI of gemcitabine (1,000 mg/m(2) over 30 min) followed by oxaliplatin (100 mg/m(2) over 2 h), which was repeated every 2 weeks. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: HAI combining gemcitabine and oxaliplatin showed promising efficacy and safety as second-line treatment for locally advanced intrahepatic cholangiocarcinoma. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}, {"polarity": 1, "orig_sen": "The tumor was diagnosed as an unresectable intrahepatic cholangiocarcinoma, and chemotherapy (a combination of gemcitabine and S-1) was initiated. ", "drug": "Gemcitabine", "disease": "Intrahepatic cholangiocarcinoma"}]